Related Experiment Video
Updated: May 18, 2026

05:53
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Combining gene expression microarray- and cluster analysis with sequence-based predictions to identify regulators of
Sören Bruhn1, Mark Katzenellenbogen, Mika Gustafsson
1The Center for Individualized Medication, Linköping University, Linköping, Sweden.
Cytokine
|September 18, 2012
Summary
This study reveals that transcription factor E2F6 inhibits the production of IL-13, a key molecule in allergic responses. Reduced E2F6 levels in allergic patients suggest its role in regulating allergy.
Area of Science:
- Immunology
- Molecular Biology
Background:
- The cytokine Interleukin-13 (IL-13) is central to allergic inflammation, influencing IgE production, mucus hypersecretion, and immune cell recruitment.
- Identifying regulatory mechanisms of IL-13 is crucial for understanding and treating allergies.
Purpose of the Study:
- To discover novel transcription factors (TFs) that regulate the expression of IL-13 in T helper 2 (Th2) cells.
- To investigate the functional role of identified TFs in the context of allergy.
Main Methods:
- Gene expression microarrays were used to analyze Th2-polarized naive T cells from healthy donors, identifying gene clusters correlated with IL-13 expression.
- Bioinformatic filtering prioritized functionally related genes within these clusters.
- Small interfering RNA (siRNA) mediated knockdowns of candidate TFs (CEBPB, E2F6, AHR) were performed in naive polarized T cells.
- Expression analysis of E2F6 was conducted in CD4+ T cells from allergic patients and healthy controls.
Main Results:
- Three TFs, CEBPB, E2F6, and AHR, were predicted to regulate IL-13.
- Knockdown of CEBPB and E2F6 significantly increased IL-13 levels, suggesting an inhibitory role.
- Allergen-challenged CD4+ T cells from allergic patients showed decreased E2F6 expression compared to healthy controls.
- CEBPB did not show altered expression in allergic patients.
Conclusions:
- E2F6 acts as an inhibitory regulator of IL-13 production in Th2 cells.
- Reduced E2F6 expression in allergic patients suggests its involvement in the pathogenesis of allergy.
- The employed analytical strategy can be broadly applied to decipher regulatory networks in Th2 cell polarization and allergic diseases.

